#United States #New York #Levi & Korsinsky #Securities Fraud #Unicycive Therapeutics

Unicycive Therapeutics, Inc. Sued for Securities Violations

In a significant legal development, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently facing a class action lawsuit initiated by Levi & Korsinsky, LLP. This lawsuit aims to seek restitution for investors who experienced financial losses as a result of alleged securities fraud during a specific timeline from March 29, 2024, to June 27, 2025. If you're an investor impacted by these allegations, it is crucial to understand your rights and the necessary steps you can take before the deadline of October 14, 2025.

Background of the Case

The lawsuit emerged from claims that Unicycive Therapeutics made misleading statements that significantly overinflated the company’s operational capabilities and regulatory compliance with the FDA. Specifically, it is alleged that the company exaggerated its readiness to meet FDA manufacturing compliance standards. Furthermore, there were claims that the potential of its new drug application regarding oxylanthanum carbonate was overstated.

This resulted in public statements that were significantly misleading, casting doubts on the integrity and reliability of the company’s evaluations. Investors need to be aware that such discrepancies can have a huge impact on stock value and shareholder trust.

What Should Affected Investors Do?

If you believe you have suffered financial losses due to your investment in Unicycive Therapeutics, taking action is critical. The lawsuit allows for shareholders to request that the Court appoint them as lead plaintiffs. However, even if you choose not to take on this role, you still have the right to participate in any potential recovery efforts.

Importantly, there are no out-of-pocket expenses for class members involved in this lawsuit. The firm Levi & Korsinsky assures that there are no costs or obligations forthcoming from your participation. This alleviates financial burdens typically associated with legal proceedings, making it more accessible for investors to pursue justice.

Why Choose Levi & Korsinsky?

For more than two decades, Levi & Korsinsky, LLP has developed a robust reputation in the field of securities litigation, successfully securing hundreds of millions of dollars for shareholders impacted by securities fraud. Their team consists of more than 70 experienced professionals dedicated to advocating for investors' rights. The firm has consistently been recognized in the ISS Securities Class Action Services' Top 50 Report, affirming their status as one of the leading securities litigation firms in the United States.

Recently, the firm's expertise has proven invaluable as they navigate complex securities cases, representing clients who may feel overwhelmed by the legal landscape. Their approach emphasizes transparency and a tenacity for fighting for the rights of shareholders.

Contact Information for Investors

If you wish to discuss your case or get more information regarding the lawsuit, you can reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email at [email protected] or by phone at (212) 363-7500. For details on filing a claim or more about being part of the lawsuit, follow this link.

In conclusion, if you were an investor in Unicycive Therapeutics and experienced losses during the specified period, it is vital to seek legal guidance promptly to ensure your rights are protected. Time is of the essence, and action must be taken before the upcoming deadline.